Skip to main content

Advertisement

Table 2 Baseline characteristics before and after propensity score matching

From: Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes

Characteristics Before matching After macthing
ARB users (n = 922) CCB users (n = 731) p value ARB users (n = 601) CCB users p value (n = 601)
Age (mean, SE) 61.7 ± 0.4 66.8 ± 0.35 <.0001 * 65.5 ± 0.4 65.6 ± 0.39 0.8268
Age over 75 years 130 (14.1%) 158 (21.6%) <.0001 * 110 (18.3%) 113 (18.8%) 0.8238
Women 316 (34.3%) 281 (38.4%) 0.0798 224 (37.3%) 225 (37.4%) 0.9525
Medical history
 Cerebrovascular disease 254 (27.5%) 208 (28.5%) 0.6837 170 (28.3%) 185 (30.8%) 0.3429
 Ischemic heart disease 317 (34.4%) 297 (40.6%) 0.009 * 228 (37.9%) 233 (38.8%) 0.7668
 Other heart disease 208 (22.6%) 193 (26.4%) 0.0703 156 (26.0%) 149 (34.8%) 0.6427
 Gout 28 (3.0%) 43 (5.9%) 0.0046 * 25 (4.2%) 25 (4.2%) 1
 Thyroid disorder 266 (28.9%) 155 (21.2%) 0.0004 * 141 (23.5%) 142 (23.6%) 0.9458
 Rheumatoid arthritis 85 (9.2%) 68 (9.3%) 0.9538 48 (8.0%) 51 (8.5%) 0.753
 Liver disease 481 (52.2%) 404 (55.3%) 0.2098 327 (54.4%) 316 (52.6%) 0.5247
 Kidney disease 688 (74.6%) 483 (66.1%) 0.0001 * 407 (67.7%) 411 (68.4%) 0.8046
 Hyperlipidemia 860 (93.3%) 678 (92.7%) 0.6764 559 (93.0%) 561 (93.3%) 0.819
 Proteinuria 463 (50.2%) 298 (40.8%) 0.0001 * 255 (42.4%) 256 (42.6%) 0.9535
Previous drugs
 Hypoglycemic drugs 226 (24.5%) 188 (25.7%) 0.574 148 (24.6%) 156 (26.0%) 0.5955
  Insulin 79 (8.6%) 44 (6.0%) 0.0498 * 36 (6.0%) 42 (7.0%) 0.4823
  Oral hypoglycemic drugs 171 (18.5%) 160 (21.9%) 0.0918 126 (21.0%) 129 (21.5%) 0.8324
 Lipid-lowering drugs 339 (36.8%) 237 (32.4%) 0.0655 201 (33.4%) 200 (33.3%) 0.9512
  Statin 286 (31.0%) 200 (27.4%) 0.1048 171 (28.5%) 169 (28.1%) 0.8981
  Fibrate 36 (3.9%) 29 (4.0%) 0.9481 21 (3.5%) 23 (3.8%) 0.7587
  Other lipid-lowering drugs 30 (3.3%) 23 (3.1%) 0.902 18 (3.0%) 18 (3.0%) 1
 Diuretics 7 (0.8%) 1 (0.1%) 0.0701 1 (0.2%) 1 (0.2%) 1
 Immunosuppressive drugs 14 (1.5%) 10 (1.4%) 0.7995 5 (0.8%) 8 (1.3%) 0.4028
 Gout drugs 59 (6.4%) 86 (11.8%) 0.0001 * 48 (8.0%) 51 (8.5%) 0.753
 Potassium preparations 2 (0.2%) 4 (0.5%) 0.2674 1 (0.2%) 0 (0%) 0.3171
 Antipsychotics 38 (4.1%) 19 (2.6%) 0.0921 18 (3.0%) 17 (2.8%) 0.8638
 Chemotherapeutic drugs 14 (1.5%) 18 (2.5%) 0.1666 11 (1.8%) 9 (1.5%) 0.652
 Steroids 57 (6.2%) 43 (5.9%) 0.7995 32 (5.3%) 33 (5.5%) 0.8985
 NSAIDs 284 (30.8%) 236 (32.3%) 0.5193 181 (30.1%) 190 (31.6%) 0.5741
 Proton pump inhibitors 126 (13.7%) 82 (11.2%) 0.136 77 (12.8%) 75 (12.5%) 0.8622
 H2 blockers 120 (13.0%) 144 (19.7%) 0.0002 * 93 (15.5%) 100 (16.6%) 0.5824
 Thyroid drugs 12 (1.3%) 13 (1.8%) 0.4301 10 (1.7%) 9 (1.5%) 0.8171
  1. Data are numbers of individuals (%) unless otherwise stated. Abbreviations: ARB; angiotensin II type I receptor blocker, CCB; calcium channel blocker, NSAID; nonsteroidal anti-inflammatory drug. *: p<0.05 (ARB vs CCB).